Quick Links



On July 19, positive results were announced from the CAPRISA 004 Phase IIb microbicide trial of 1% tenofovir gel, which was tested in 889 South African women. Overall, there were 39 percent fewer infections among women who received 1% tenfovir gel compared to women who received the placebo gel. For more information, click through the links below.

CAPRISA 004 is a Phase IIb, two-arm, double-blind, randomized, controlled microbicide trial that compared the effectiveness of a 1% tenofovir gel with a placebo gel for the prevention of HIV infection in women. Nearly 900 HIV-negative, sexually active women between the ages of 18 to 40 years were enrolled at two research sites: Durban and Vulindlela, located in KwaZulu-Natal, South Africa.

The first participant was enrolled on 23 May 2007, and results from the trial were announced at the International AIDS Conference in Vienna. The data was officially presented (and published in Science) on Tuesday, July 20 at 1pm CET (8am ET) at a special session, “Safety and effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial”. This session is available by webcast at the Kaiser Family Foundation website.

Essential readings and materials:
Webcasts and slides

Peer-reviewed publications

AVAC publications

Additional Background
AVAC: Global Advocacy for HIV Prevention
101 West 23rd Street   ·  New York, NY  
+1 212.796.6423 (main)   ·  avac@avac.org
Copyright 2014, All rights reserved.
Design by Lomangino Studio | Powered by Orchid Suites Orchid ver. 4.7.6.